EyePoint Pharmaceuticals (EYPT)

EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.

Company profile

Nancy Sue Lurker
Fiscal year end
Former names
pSivida Corp., pSivida LTD
EyePoint Pharmaceuticals US, Inc. • pSiMedica Limited • EyePoint Pharmaceuticals Securities Corporation • Icon Bioscience, Inc. ...
IRS number

EYPT stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
Low target
High target
HC Wainwright & Co.
4 Aug 22
Chardan Capital
7 Jul 22

Investment data

Data from SEC filings
Securities sold
Number of investors


5 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Jun 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 82.28M 82.28M 82.28M 82.28M 82.28M 82.28M
Cash burn (monthly) 6.47M 3.79M 6.41M 5.91M 6.37M 5.31M
Cash used (since last report) 19.79M 11.6M 19.59M 18.06M 19.5M 16.25M
Cash remaining 62.49M 70.69M 62.69M 64.22M 62.79M 66.04M
Runway (months of cash) 9.7 18.6 9.8 10.9 9.8 12.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
7 Sep 22 Jay S. Duker Stock Option Common Stock Grant Acquire A No No 9.45 65,300 617.09K 65,300
11 Jul 22 Zaderej Karen L. Stock Option Common Stock Grant Acquire A No No 8.22 22,000 180.84K 22,000
11 Jul 22 Zaderej Karen L. RSU Common Stock Grant Acquire A No No 0 6,000 0 6,000
23 Jun 22 Anthony P Adamis Stock Option Common Stock Grant Acquire A No No 7.54 22,000 165.88K 22,000
23 Jun 22 Anthony P Adamis RSU Common Stock Grant Acquire A No No 0 6,000 0 6,000
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

  • We will likely need additional capital to fund our operations. If we are unable to obtain sufficient capital, we will need to curtail and reduce our operations and costs and modify our business strategy.
  • We may never achieve profitability from future operations.
  • The ongoing novel coronavirus (COVID-19) pandemic has had and will likely continue to have a material and adverse impact on our business.
  • We will need to raise additional capital in the future, which may not be available on favorable terms and may be dilutive to stockholders or impose operational restrictions.
  • We must maintain compliance with the terms of our Credit Facilities or receive a waiver for any non-compliance. Our failure to comply with the covenants or other terms of the Credit Facilities, including as a result of events beyond our control, could result in a default under the SVB Loan Agreement that would materially and adversely affect the ongoing viability of our business.
  • Our Loan Agreement contains restrictions that limit our flexibility in operating our business.
  • Certain potential payments to the Lenders could impede a sale of our company.
  • To service our indebtedness, we will require a significant amount of cash and our ability to generate cash depends on many factors beyond our control.
  • Our profitability will be impacted by our obligations to make royalty and milestone payments to the former securityholders of Icon Bioscience, Inc. and other third-party collaborators.
  • Our ability to use our net operating loss carryforwards and other tax attributes may be limited.
  • Clinical trial results may fail to support approval of EYP-1901 or our other product candidates.
  • We may expend significant resources to pursue our lead product candidate, EYP-1901 for the potential treatment of wet AMD, and fail to capitalize on the potential of EYP-1901, or our other product candidates, for the potential treatment of other indications that may be more profitable or for which there is a greater likelihood of success.
  • Initial results from a clinical trial do not ensure that the trial will be successful and success in early stage clinical trials does not ensure success in later-stage clinical trials.
  • We face risks related to health epidemics and outbreaks, including the Pandemic, which could significantly disrupt our preclinical studies and clinical trials.
  • We may find it difficult to enroll patients in our clinical trials, which could delay or prevent clinical trials of our product candidates.
  • We are largely dependent on the clinical and future commercial success of our lead product candidate, EYP-1901.
  • Our current business strategy relies in part on our ability to successfully commercialize YUTIQ and DEXYCU and in the U.S. Our approved products may not achieve market acceptance or be commercially successful.
  • We could be adversely affected by our exposure to customer concentration risk.
  • Our products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, including DEXYCU pass-through status, which could harm our business.
  • If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
  • Even though regulatory approvals for YUTIQ and DEXYCU have been obtained in the U.S., we will still face extensive FDA regulatory requirements and may face future regulatory difficulties.
  • Our relationships with physicians, patients and payors in the U.S. are subject to applicable anti-kickback, fraud and abuse laws and regulations. In addition, we are subject to patient privacy regulation by both the federal government and the states in which we conduct our business. Our failure to comply with these laws could expose us to criminal, civil and administrative sanctions, reputational harm, and could harm our results of operations and financial conditions.
  • If the market opportunities for our products and product candidates, including EYP-1901, are smaller than we believe they are, our results of operations may be adversely affected and our business may suffer.
  • If any of our products have newly discovered or developed safety problems, our business would be seriously harmed.
  • The Affordable Care Act and any changes in healthcare laws may increase the difficulty and cost for us to commercialize DEXYCU and YUTIQ in the U.S. and affect the prices we may obtain.
  • Patient assistance programs for pharmaceutical products have come under increasing scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing prices or demand for our products, harming our business or reputation, or subjecting us to fines or penalties.
  • If competitive products are more effective, have fewer side effects, are more effectively marketed and/or cost less than our products or product candidates, or receive regulatory approval or reach the market earlier, our product candidates may not be approved, and our products or product candidates may not achieve the sales we anticipate and could be rendered noncompetitive or obsolete.
  • DEXYCU is an intraocular suspension that delivers dexamethasone, a corticosteroid that is associated with certain adverse side effects in the eye, which may affect the success of DEXYCU for the treatment of post-operative inflammation.
  • If the FDA or other applicable regulatory authorities approve generic products that compete with any of our products or product candidates, it could reduce our sales of those products or product candidates.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of YUTIQ and DEXYCU, and any other product candidates that we may develop and commercialize, including EYP-1901.
  • If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate to protect our product candidates, our competitors could develop and commercialize technology and products similar to ours, and our competitive position could be harmed.
  • We may become involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which could be uncertain and could harm our business.
  • Changes in either U.S. or foreign patent law or interpretation of such laws could diminish the value of patents in general, thereby impairing our ability to protect our products or product candidates.
  • We may be subject to claims asserting that our employees, consultants, independent contractors and advisors have wrongfully used or disclosed confidential information and/or alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.
  • Intellectual property rights do not prevent all potential threats to competitive advantages we may have.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • If our trademarks are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • The development and commercialization of our lead product candidate, EYP-1901, is dependent on intellectual property we license and API supply of vorolanib from Equinox Science. If we breach our agreement with Equinox or the agreement is terminated, we could lose license rights that are material to our business.
  • If we are unable to maintain our agreement with ImprimisRx to co-promote DEXYCU, we may be unable to generate significant revenue from this product.
  • If we encounter issues with our CMOs or suppliers, we may need to qualify alternative manufacturers or suppliers, which could impair our ability to sufficiently and timely manufacture and supply DEXYCU.
  • We use our own facility for the manufacturing of YUTIQ and rely on third party suppliers for key components, and any disruptions to our suppliers’ operations could adversely affect YUTIQ’s commercial viability.
  • Our YUTIQ manufacturing operations depend on our Watertown, MA facility. If this facility is destroyed or is out of operation for a substantial period of time, our business may be adversely impacted.
  • If our CROs, vendors and investigators do not successfully carry out their responsibilities or if we lose our relationships with them, our development efforts with respect to our product candidates could be delayed.
  • The trading price of the shares of our common stock has been highly volatile, and purchasers of our common stock could incur substantial losses.
  • EW Healthcare and Ocumension own a substantial amount of our common stock and can exert significant control over matters subject to stockholder approval, which would prevent new investors from influencing significant corporate decisions.
  • Certain covenants related to our share purchase agreement with Ocumension may restrict our ability to obtain future financing and cause additional dilution for our stockholders.
  • Provisions in our bylaws provide for indemnification of officers and directors, which could require us to direct funds away from our business and the development of our product candidates.
  • We will need to grow the size of our organization, and we may experience difficulties in managing this growth.
  • If we fail to comply with data protection laws and regulations, we could be subject to government enforcement actions, which could include civil or criminal penalties, as well as private litigation and/or adverse publicity, any of which could negatively affect our operating results and business.
Management Discussion
  • We are a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. Our pipeline leverages our proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration (“wet AMD”), the leading cause of vision loss among people 50 years of age and older in the United States. We also have two commercial products: YUTIQ®, a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, a single dose treatment for postoperative inflammation following ocular surgery. We are also advancing YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application (sNDA) strategy.

Content analysis

H.S. senior Avg
New words: ADR, Affordable, AMP, Anthony, appealed, ASP, attempted, AxoGen, bill, biological, biopharmaceutical, biosimilar, bundled, buy, care, carefully, CDE, ceiling, civil, Coast, Consumer, context, correspondingly, court, CST, CY, decision, demonstrating, depletion, device, discarded, dispensed, disproportionate, dispute, diversion, DoD, draft, evidence, face, factor, faster, FCP, federal, formula, free, FSS, furnished, gap, gave, governmental, harm, hinder, HRSA, imposition, inability, inapplicability, Increasingly, inflation, inpatient, intention, intentionally, introduced, Karen, knowingly, larger, law, leasehold, lengthy, lessee, monetary, network, newly, occupy, OCT, optical, overcharge, overcharging, pace, packaged, packaging, panel, passed, payer, percent, pharmacy, predetermined, prefer, prescription, President, proceeding, procurement, promptly, published, randomized, recoup, reform, Register, regulation, reinstated, relaxation, reliable, rely, rendering, resolution, resolved, Retail, scrutiny, source, specific, specifically, statute, statutorily, therapy, Tony, transitional, trend, tricare, unclear, upward, VA, vascular, widely, wrap, Zaderej
Removed: add, ASU, calculating, call, clarify, delivered, filed, framework, freestanding, fully, Hedging, inhibitor, kinase, locally, measure, Mine, modification, noncancelable, permitted, Qualitative, Quantitative, Republic, retain, standard, Subtopic, Summary, Topic, tyrosine, Unregistered, written